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Abstract
Introduction MUC1 is a cell-surface glycoprotein that
establishes a molecular barrier at the epithelial surface and
engages in morphogenetic signal transduction. Alterations in
MUC1 glycosylation accompany the development of cancer and
influence cellular growth, differentiation, transformation,
adhesion, invasion, and immune surveillance. A 20-amino-acid
tandem repeat that forms the core protein of MUC1 is
overexpressed and aberrantly glycosylated in the majority of
epithelial tumors. AS1402 (formerly R1550) is a humanized
IgG1k monoclonal antibody that binds to PDTR sequences
within this tandem repeat that are not exposed in normal cells.
AS1402 is a potent inducer of antibody-dependent cellular
cytotoxicity (ADCC), specifically against MUC1-expressing
tumor cells. The objective of this study was to determine the
safety, tolerability, and pharmacokinetic (PK) characteristics of
AS1402 monotherapy in patients with locally advanced or
metastatic MUC1-positive breast cancer that had progressed
after anthracyclines- and taxane-based therapy.
Methods Patients received AS1402 over a 1- to 3-hour
intravenous (i.v.) infusion at doses between 1 and 16 mg/kg,
with repeated dosing every 1 to 3 weeks (based on patient-
individualized PK assessment) until disease progression. Serum
AS1402 levels were measured at multiple times after i.v.
administration. Human anti-human antibody (HAHA) responses
were measured to determine the immunogenicity of AS1402.
Noncompartmental pharmacokinetic parameters were
determined and were used to assess dose dependency across
the dose range studied.
Results Twenty-six patients were treated. AS1402 was
generally well tolerated. Two grade 3/4 drug-related adverse
events were reported, both at the 3-mg/kg dose. Neither was
observed in expanded or subsequent dosing cohorts. No anti-
human antibodies were detected. Plasma concentrations of
AS1402 appeared to be proportional to dose within the 1- to
16-mg/kg dose range assessed, with a mean terminal half-life of
115.4 ± 37.1 hours.
Conclusions Repeated iv administration of AS1402 was well
tolerated, with a maximum tolerated dose (MTD) exceeding 16
mg/kg, the highest dose administered in this study. The half-life
and exposure of AS1402 were such that weekly dosing could
achieve plasma concentrations corresponding to the maximal
ADCC activity observed in vitro. A phase II study is ongoing to
evaluate the clinical activity of AS1402 in patients with
advanced breast cancer.
Trial registration ClinicalTrials.gov Identifier: NCT00096057.
ADCC: antibody-dependent cellular cytotoxicity; AE: adverse event; ALT: alanine transaminase; AST: aspartate transaminase; AUC: area under the curve; 
CHO: Chinese hamster ovary; CL: clearance; CTCAE: Common Terminology Criteria for Adverse Events; DLT: dose-limiting toxicity; ECHO: echocardi-
ogram; ELISA: enzyme-linked immunosorbant assay; HAHA: human anti-human antibody; huHMFG: humanized human milk-fat globule; ICH GCP: Inter-
national Conference on Harmonisation of Good Clinical Practice; i.v.: intravenous; MTD: maximum tolerated dose; MUGA: multigated acquisition scan; 
NCI: National Cancer Institute; NK: natural killer; PBMC: peripheral blood mononuclear cell; PK: pharmacokinetic.Breast Cancer Research    Vol 11 No 5    Pegram et al.
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Introduction
MUC1 is a cell-surface glycoprotein that establishes a molec-
ular barrier at the epithelial surface and engages in morphoge-
netic signal transduction. Alterations in MUC1 glycosylation
accompany the development of cancer and influence cellular
growth, differentiation, transformation, adhesion, invasion, and
immune surveillance [1]. MUC1 is overexpressed in more than
90% of breast cancers and the majority of epithelial tumors
and has prognostic value in a number of malignancies, includ-
ing breast cancer [2]. MUC1 is expressed as a stable het-
erodimer composed of two subunits derived from a single
polypeptide chain, after cleavage in the endoplasmic reticulum
[3]. The MUC1 N-terminal subunit contains a variable number
of 20-amino-acid tandem repeats that are modified by O-
linked glycans. The MUC1 C-terminal subunit comprises a 58-
amino-acid extracellular domain, a 28-amino-acid transmem-
brane domain, and a 72-amino-acid cytoplasmic tail. This C-
terminal domain accumulates in the cytosol of transformed
cells and is delivered to the nucleus and mitochondria [4]. The
MUC1 cytoplasmic domain associates with β-catenin and with
the p53 tumor suppressor and is subject to phosphorylation
by the epidermal growth factor receptor, c-Src, and glycogen
synthase kinase-3β, suggesting a role for MUC1 in the erbB
receptor kinase and Wnt signaling pathways [5].
MUC1 is often highly overexpressed in breast cancer relative
to normal breast epithelial cells. Recently, Wei et al. [6] dem-
onstrated that the C-terminal fragment of MUC1 associates
with the DNA-binding domain of the estrogen receptor. Such
binding stabilized the estrogen receptor by reducing ubiquiti-
nation and proteasomal degradation of the estrogen receptor.
MUC1 also increased recruitment of coactivators SRC1 and
GRIP1 and was associated with increased ER-α-mediated
transcription. Taken together, these data suggest a role for
MUC1 oncoprotein in estrogen-mediated cell growth and sur-
vival of breast cancer cells.
Antibodies targeting MUC1 epitopes studied in human breast
tumor biopsies bind to at least 90% of invasive breast neo-
plasms [7]. The overexpression of MUC1 correlates with
adhesion and invasion of breast cancer cells in vitro [8].
Breast cancer patients who demonstrate MUC1 overexpres-
sion in greater than 75% of tumor cells and aberrant subcellu-
lar localization (cytoplasmic and membranous) have
significantly poorer disease-free and overall survival [9].
AS1402 (formerly R1550) is a humanized IgG1κ monoclonal
antibody (huHMFG1, [10]) which binds (Kd~1 nmol/L) the
extracellular MUC1 peptide sequence, PDTR. These
sequences are not exposed in normal cells because of full gly-
cosylation, but aberrant glycosylation in cancer cells exposes
the epitope to the antibody. AS1402 is a potent inducer of
antibody-dependent cellular cytotoxicity (ADCC), specifically
against MUC1-expressing tumor cells.
Snijdewint  et al. [11] demonstrated ADCC elicited by
AS1402 in vitro in the breast tumor cell line ZR-75-1, in three
bone marrow-derived tumor cell lines from breast cancer
patients (KM22, 1590, HG15), and in Chinese hamster ovary
(CHO) cells transfected with the human MUC1 gene, by using
peripheral blood mononuclear cells (PBMCs) from healthy
donors. Cell lines that did not express human MUC1 were not
susceptible to ADCC in the presence of AS1402. Very weak
or no killing of the MUC1-positive target cell line with human
PBMCs was noted in the absence of AS1402. These authors
also demonstrated a strong reduction in specific AS1402-
dependent cell killing of ZR-75-1 cells when the PBMCs were
depleted of CD56+cells (that is, natural killer (NK) cells). Par-
tial to complete depletion (> 50% to 90%) of either CD4+,
CD8+, or CD19+cells (that is, T and B cells) from the PBMCs
did not significantly reduce the ADCC. Moreover, the ADCC
activity of AS1402 was shown to be dependent on the involve-
ment of the Fcγ III receptor (CD16) on NK cells.
Immunotherapy for the treatment of cancer is an attractive
alternative to cytotoxic chemotherapy. Since the approval in
1997 of rituximab (anti-CD20) for the therapy of non-Hodgkin
lymphoma, several other antibodies have been licensed for dif-
ferent cancers. Many of these antibodies act by inhibiting sig-
nal transduction, and others, such as rituximab, trastuzumab
(anti-HER2), and alemtuzumab (anti-CD52), act in addition
through ADCC. NK cells of the body's immune system are
directed to destroy antibody-targeted tumor cells. It has been
reported that a natural humoral immune response to MUC1
protein in early breast cancer patients results in improved dis-
ease-free survival [12]. Interestingly, those patients with
endogenous anti-MUC1 antibodies had a significantly higher
probability of freedom from distant metastases, raising the
possibility that the antibodies may be destroying circulating
MUC1-positive tumor cells.
The objectives of this multicenter phase I study were to deter-
mine the safety and pharmacokinetics as well as the maximal
tolerated dose (MTD) of AS1402 in patients with metastatic
breast cancer.
Materials and methods
Patient eligibility
Patients with advanced or metastatic breast cancer were eligi-
ble for this clinical trial. Before initiation of the study at each
investigational site, relevant study documentation was submit-
ted to and approved by the responsible local ethics commit-
tee: Colorado Multiple Institutional Review Board, Aurora, CO;
Ochsner Clinical Foundation Institutional Review Board, New
Orleans, LA; The University of Texas, MD Anderson Cancer
Center Surveillance Committee, Houston, TX; Office for the
Protection of Research Subjects, Los Angeles, CA; and West-
ern Institutional Review Board, Olympia, WA.Available online http://breast-cancer-research.com/content/11/5/R73
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The guidelines of the World Medical Association Declaration
of Helsinki in its revised edition (Edinburgh, Scotland, October
2000), the guidelines of ICH GCP (CPMP/ICH/135/95), as
well as the demands of national drug and data-protection laws
and other applicable regulatory requirements were strictly fol-
lowed. Written informed consent was obtained from each
patient before any study-specific screening procedures were
undertaken.
Inclusion criteria
Patients had to have histologically or cytologically confirmed
breast cancer with overexpression of the MUC1 antigen on
central immunohistochemistry assessment. Subjects had
locally advanced or metastatic disease and had to have
received no more than three prior chemotherapy regimens
(including adjuvant/neoadjuvant therapy). They had to have
previously received, with unsuccessful results, an anthracy-
cline and a taxane in any combination for the treatment of
breast cancer, unless ineligible for these treatments owing to
comorbidities or refusal of therapy. In addition, patients whose
tumors were HER2 positive had to have relapsed after treat-
ment with trastuzumab (Herceptin). No restriction was posed
for prior hormonal or biologic therapies or both.
Exclusion criteria
Concurrent cytotoxic chemotherapy for metastatic breast can-
cer was not allowed. Patients with a left ventricular ejection
fraction of less than 45%, as determined by multigated acqui-
sition scan (MUGA) or echocardiogram (ECHO) scans within
4 weeks of study entry, were excluded.
Treatment plan
It was planned to test doses of 1 mg/kg, 3 mg/kg, 9 mg/kg,
and 16 mg/kg, according to the toxicity and pharmacokinetic
(PK) profile observed at prior dose levels. The dose of
AS1402 would not be increased beyond 16 mg/kg, as this
was considered to be the maximum viable dose. It was
planned that 24 evaluable patients would be recruited into the
study, with six patients allocated to each treatment group.
AS1402 was administered over a 60-minute period for the 1-
mg/kg and 3-mg/kg cohorts. The infusion times were
increased to 120 minutes and 180 minutes for the 9-mg/kg
and 16-mg/kg cohorts, respectively. For patients in the 1-mg/
kg and 3-mg/kg cohorts, the first two treatments were given
21 days apart. The half-life after the first dose was determined
for each patient, and the dosing intervals for dose 3 onward
were set on an individual patient basis to be within ± 3 days of
the half-life, in multiples of 7 days. For patients in the 9-mg/kg
and 16-mg/kg cohorts, the dosing interval in multiples of 7
days was determined for the whole cohort, based on PK anal-
ysis of the data from all previous cohorts. Patients remained on
treatment until they had disease progression or dose-limiting
toxicity (DLT).
Cohort expansion to nine patients occurred if DLT was
observed in any cohort. Adverse events (AEs) were coded
according to the National Cancer Institute (NCI) Common Ter-
minology Criteria for Adverse Events (CTCAE), version 3.0.
DLT was defined as nonhematologic and hematologic grade 3
or greater, grade 2 or greater allergic reaction (bronchospasm
and generalized urticaria), or grade 2 or greater autoimmune
reaction. The MTD was defined as the highest dose studied at
which the incidence of DLTs was less than 33%.
In each cohort, a single patient was treated initially and
observed for at least 21 days. If no DLT occurred in the first
patient, then two additional patients were treated at the same
dose level and observed for 21 days. If either none or one of
the three patients experienced a DLT, then the cohort was
expanded to six patients. If at any given dose level, the first
patient experienced a DLT, then one more patient was enrolled
at that dose level and observed for 21 days before accrual of
additional patients.
Analytic methods and pharmacokinetics
Blood samples for pharmacokinetic analysis were drawn
before infusion, at the end of infusion, at 4, 6, and 12 h after
the start of infusion, and on days 2, 3, 4, 5, 8, 11, and 15. Anal-
ysis of AS1402 in human serum samples used a two-step
solid-phase enzyme-linked immunosorbant assay (ELISA) with
bovine serum albumin conjugated to the 20-amino-acid pep-
tide sequence recognized by AS1402 as the bound antigen
[11]. The lower limit of detection of this assay was 0.5 μg/ml.
Noncompartmental pharmacokinetic parameters were calcu-
lated from individual patient serum concentration-time profiles
by using WinNonlin v4.0 (Pharsight, Mountain View, CA,
USA). The maximum serum concentration of AS1402 (Cmax)
was obtained directly from observed data. The elimination half-
life was estimated from the terminal phase of the serum con-
centration-time profile. The area under the serum concentra-
tion-time profile extrapolated to infinity (AUC0-∞) was
calculated by using the log-linear trapezoidal rule. The total
serum clearance (CL) and the volume of distribution at steady
state (Vss) were calculated by using the standard software for-
mulae of CL = Dose/AUC0-∞ and Vss = CL*MRT (where the
mean residence time was derived from the area under the first
moment versus time curve).
Levels of tumor markers (CA15.3, CEA, and CA27.29) were
measured by using a chemiluminometric assay at time points
to coincide with radiologic assessments.
Results
Patient demographics
Patient demographics are shown in Table 1. A total of 26
female patients were enrolled in four dosing cohorts. Twenty-
three percent of patients with known HER-2 status (5 of 22)
were HER2-positive, in line with published prevalence dataBreast Cancer Research    Vol 11 No 5    Pegram et al.
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[13]. All patients had progressive disease after chemotherapy,
with trastuzumab therapy also having failed for the HER2-pos-
itive patients.
Clinical safety and tolerability
All 26 enrolled patients were evaluable for safety. The 1-mg/kg
cohort enrolled three patients; the 3-mg/kg cohort was
expanded to nine patients owing to the occurrence of a DLT.
Consequently, an additional observation period before accrual
of additional patients was implemented; no additional DLTs
were observed that prevented enrollment into the subsequent
cohort. The 9- and 16-mg/kg cohorts enrolled six and eight
patients, respectively. The median number of doses received
per patient was three (range, three to four), four (one to 13),
six (four to 21), and 6.5 (three to 15) in cohorts 1, 2, 3, and 4,
respectively. Although an MTD was not reached, the dose of
AS1402 was not escalated above 16 mg/kg, which was con-
sidered to be the maximum viable. No patients with positive tit-
ers for human anti-human antibody (HAHA) were found in any
cohort.
A summary of the patient- and investigator-reported drug-
related clinical AEs is shown in Table 2. AS1402 was gener-
ally well tolerated, with few clinically significant drug-related
AEs reported. The most frequently reported AE was grade 1
or 2 study drug-related reactions, (26% grade 1, 17.4% grade
2), described as nausea, fatigue, pyrexia, and pain or discom-
fort at the i.v. infusion site. The next most frequent adverse
event was gastrointestinal toxicity (grade 1) in the form of nau-
sea, constipation, or stomatitis. Reversible elevations of
hepatic-function tests also were observed in some patients
(grade 1: 8.7%, grade 2: 8.7%, grade 3: 4.3%, and grade 4:
4.3%).
Grade 3/4 drug-related AEs were reported for two patients
among the 26 dosed with AS1402, both in the 3-mg/kg
Table 1
Patient demographics
Female patients enrolled (n) 26
Age (years) (median/min/max) 55.5/32.0/72.0
Mean weight ± SD (kg) (range) 73.1 ± 14.6 (50-108)
Median months from diagnosis of metastatic disease to study entry (months) (range) 14.4 (1.6-67.2)
WHO performance status (n = 26)
0 17
1 9
Steroid hormone receptor status (n = 24)
ER and/or PR+ 18
ER and PR- 8
HER2 statusa (n = 22)
HER2+ 5
HER2- 17
Metastatic tumor sites (n = 26)
Lung 17
Bone 15
Liver 13
Lymph nodes 12
Lesions on more than one organ 22
Race (n = 26)
Caucasian 20
Asian 2
Hispanic 1
African-American 3
aHER2 status confirmed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).Available online http://breast-cancer-research.com/content/11/5/R73
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cohort. One patient had elevated ALT (grade 3), elevated AST
(grade 4), jaundice (grade 3), increased blood bilirubin (grade
3), and elevated γ-glutamyl transferase (grade 3) that were
considered possibly drug related and constituted a DLT.
These events were of 0 to 2 days' duration, with the exception
of jaundice, which persisted from day 14 to the time of death
at day 26 due to progressive disease involving liver and bone
metastases. Another patient experienced grade 4 hyperglyc-
emia that was possibly related to treatment. This resolved after
14 days after antiglycemic therapy and delay in administration
of AS1402. No grade 3/4 AE was observed in expanded or
subsequent dosing cohorts. No grade 5 AEs were found. One
patient was discontinued from the study owing to metastases
to the central nervous system, and one patient died during the
study of metastatic breast cancer; neither was considered to
be related to the study medication. Eight patients died after
they had been discontinued from the study; six died of breast
cancer, and one died because of collapse of the lung. For one
patient, the cause of death was unknown.
Pharmacokinetics
The mean serum concentrations of AS1402 after the first dose
for the 1-, 3-, 9-, and 16-mg/kg treatment groups are shown in
Figure 1. A multiexponential decline in serum concentrations
of AS1402 was observed, and systemic exposure increased
with each successive dose escalation. Steady-state serum
concentrations did not appear to have been reached in the
majority of the patients during study treatment. The mean ter-
minal half-life of AS1402 appeared shorter at the higher dose
levels (111 and 102 h at the higher two doses, compared with
147 and 128 h at the lower two doses). Because the sampling
schedule was shorter for the higher-dose cohorts, the shorter
half-life values are likely to represent an earlier phase of the
serum concentration-time curve, potentially including a partial
distribution phase along with a terminal elimination phase.
Although the initial doses were given 21 days apart, the PK
data supported a reduction of the dosing interval to 7 days.
The calculated noncompartmental pharmacokinetic parame-
ters are summarized in Table 3. Clearance of AS1402 from
serum was consistent across all dose cohorts, with mean val-
ues ranging from 0.34 to 0.49 ml/h/kg. The volume of distribu-
tion was broadly comparable across the treatment cohorts,
with mean values ranging from 50.3 to 68.2 ml/kg. AS1402
exhibited linear pharmacokinetics with respect to dose across
the 1- to 16-mg/kg dose range, as demonstrated by the dose-
Table 2
Drug-related adverse events (n = 26 patients)
Category of AE Grade 1 Grade 2 Grade 3 Grade 4
General disorders
(fatigue, pain, pyrexia, catheter-site edema, injection site burning)
6 (26.0%) 4 (17.4%) - -
GI disorders 
(aphthous stomatitis, constipation, nausea)
4 (17.4%) - - -
Nervous system disorders
(dysguesia)
2
(8.7%)
-- -
Skin and subcutaneous tissue disorders
(rash, alopecia)
5 (19.2%) - - -
Laboratory investigations
(↑ ALT, ↑ AST, ↑ GGT, ↑ bilirubin)
-1
(4.3%)
1
(4.3%)
1
(4.3%)
Metabolism and nutritional disorders 
(anorexia, hyperglycemia)
2
(8.7%)
-- 1
(4.3%)
Hepatobiliary disorder
(jaundice)
--1
(4.3%)
-
Figure 1
Mean AS1402 serum concentration-versus-time profiles (± SD) after  i.v. administration to patients at doses of 1 mg/kg (circle), 3 mg/kg (tri- angle), 9 mg/kg (square), or 16 mg/kg (diamond) Mean AS1402 serum concentration-versus-time profiles (± SD) after 
i.v. administration to patients at doses of 1 mg/kg (circle), 3 mg/kg (tri-
angle), 9 mg/kg (square), or 16 mg/kg (diamond). An antibody concen-
tration of 10 μg/ml was sufficient to elicit ADCC to kill breast cancer 
cells in vitro.Breast Cancer Research    Vol 11 No 5    Pegram et al.
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proportional increase in Cmax and AUC0-∞ (Figure 2a and 2b,
respectively).
Tumor markers
Sixteen (62%) patients had elevated CA15.3 levels at screen-
ing and throughout the study. CEA levels remained relatively
unaltered by treatment with AS1402, and no clear trends in
correlation between CA27.29 and exposure to AS1402 were
found.
Clinical activity
Twenty-two patients were evaluable for efficacy. Objective
clinical response was assessed according to RECIST. No
objective complete or partial responses were recorded during
dose escalation; five (22.7%) patients had a best overall
response of stable disease (one in the 3-mg/kg cohort, one in
the 9-mg/kg cohort, and three in the 16-mg/kg cohort); stable
disease durations ranged from 80 to 119 days. All these
patients had progressive disease before antibody therapy. The
median time to tumor progression by cohort is summarized in
Table 4.
Discussion
These are the first data from a clinical study of a MUC1-target-
ing naked antibody. In total, 26 evaluable patients were
recruited into the study; doses of 1 mg/kg, 3 mg/kg, 9 mg/kg,
and 16 mg/kg were tested. The 16-mg/kg dose was consid-
ered to be the maximum viable dose. Repeated i.v. administra-
tion of AS1402 was well tolerated, with an MTD exceeding 16
mg/kg. The majority of drug-related AEs were NCI CTC grade
1 or 2. Infusion-associated reactions were generally CTC
grade 1. No incidents of patients with positive titers for anti-
human antibodies were found during the study.
Systemic exposure of AS1402 appears to be linear with
respect to dose within the 1- to 16-mg/kg dose range
assessed. This linear relation between exposure and dose was
suggestive that the pharmacokinetic disposition of this human-
Table 3
Noncompartmental pharmacokinetic parameters for AS1402 after i.v. administration (mean ± SD)
Dose cohort 1 mg/kg
(n = 3)
3 mg/kg
(n = 9)
9 mg/kg
(n = 6)
16 mg/kg
(n = 8)
Cmax
(μg/ml)
21.1 ± 4.67 73.5 ± 11.8 209 ± 17.3 514 ± 232
Half-life (h) 147 ± 19.3 128 ± 50.6 111 ± 23.0 102 ± 22.6
AUC0-∞(μg*h/ml) 2,399 ± 1,205 9,032 ± 3,314 24,757 ± 3,625 49,302 ± 10,971
CL (ml/h/kg) 0.486 ± 0.213 0.386 ± 0.174 0.369 ± 0.0488 0.337 ± 0.0648
Vss (ml/kg) 68.2 ± 16.9 54.6 ± 12.2 56.8 ± 7.14 50.3 ± 18.56
Figure 2
AS1402 Cmax (a) and AS1402 AUC0-∞ (b) versus dose proportionality in patients receiving doses of 1 mg/kg (circle), 3 mg/kg (triangle), 9 mg/kg  (square), or 16 mg/kg (triangle) AS1402 Cmax (a) and AS1402 AUC0-∞ (b) versus dose proportionality in patients receiving doses of 1 mg/kg (circle), 3 mg/kg (triangle), 9 mg/kg 
(square), or 16 mg/kg (triangle).Available online http://breast-cancer-research.com/content/11/5/R73
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ized anti-MUC1 antibody is not dependent on saturable distri-
bution or clearance processes, which might be expected if
significant binding to circulating antigen occurred in vivo. Pre-
vious in vitro studies have shown that the affinity of AS1402
for its antigen in solution is 100-fold lower than that for cell-
bound antigen, which provides a good rationale for the lack of
binding to circulating antigen in vivo [14]. The mean terminal
half-life of AS1402 was measured to be approximately 5 days,
which suggests that weekly dosing of AS1402 at doses
greater than 3 mg/kg would be required to achieve serum anti-
body concentrations at or above the 10 μg/ml observed for
maximal ADCC activity in vitro. A 5-day half-life for AS1402, a
humanized antibody (approximately 90% human), is compara-
ble with the published values of 4.7 days for cetuximab (chi-
meric anti-EGFR, approximately 66% human) and 7.5 days for
panitumumab (fully human anti-EGFR) [15]. Although the ini-
tial proposed dosing interval was 21 days, a weekly adminis-
tration would be an acceptable addition to standard treatment
regimens.
The best overall response was stable disease (achieved by
five patients), and the median time to disease progression
ranged from 39 to 44 days. Patients enrolled into this study
had been heavily pretreated and had progressive disease on
entry. In light of this, the fact that stable disease was observed
in five patients warrants further investigation in less heavily pre-
treated or chemotherapy-naïve patients.
Antibodies have, in general, been most successfully applied as
elements of combination regimens. An antibody against
MUC1 has the attraction in this context that its target is over-
expressed in around 90% of human breast cancers. Moreover,
some data suggest a rationale for combination with existing
breast cancer therapies, especially anti-estrogens. The MUC1
C-terminal subunit interacts with ERα, and this interaction is
stimulated by 17β-estradiol (E2). Direct binding of MUC1 to
the ERα DNA-binding domain stabilizes ERα by blocking its
ubiquitination and degradation. Furthermore, MUC1 stimu-
lated ERα-mediated transcription and contributed to the E2-
mediated growth and survival of breast cancer cells [6].
Reports from a phase III trial of a breast cancer vaccine, Ther-
atope, indicated that aromatase inhibitors may increase
ADCC, adding to the rationale for combining anti-MUC1 anti-
bodies with this approach to estrogen reduction. In a study
reported by Braun et al. [16], tumor cells incubated with the
aromatase inhibitor, formestane, became sensitized to killing
by monocyte-mediated, antibody-dependent cellular cytotoxic-
ity by an anti-MUC1 antibody. These observations led the
authors to conclude that a hormone-based treatment may col-
laborate with antigen-specific tumor immunity to produce
improved tumor control in patients with breast cancer. Results
from the phase III study showed that patients receiving Therat-
ope plus concomitant hormone therapy had a prolonged sur-
vival over those patients receiving a control vaccine plus
hormone therapy [17]. Survival in these patients was also pos-
itively associated with immunoglobulin G titers to the underg-
lycosylated mucin-associated glycoprotein, an antigen similar
to that recognized by AS1402. A phase III trial combining tras-
tuzumab with the aromatase inhibitor anastrazole found that
patients treated with the combination therapy had a signifi-
cantly higher response rate and progression-free survival than
did patients receiving anastrazole alone [18].
Conclusions
Data obtained from the AS1402 phase I clinical trial, together
with the role of the MUC1 oncoprotein in stabilization and acti-
vation of the estrogen receptor and the potential for aromatase
inhibitors to increase ADCC, provide a clear basis for a phase
II study combining an anti-MUC1 antibody with endocrine ther-
apy. Letrozole has been shown, in three separate trials, to be
superior to anastrazole in reducing circulating estrogen levels
[19]. A phase II randomized, open-label, multicenter study of
weekly infusions of 9 mg/kg AS1402 in combination with
letrozole as first-line treatment in postmenopausal women with
locally advanced or metastatic breast cancer is ongoing.
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